[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
Vaught, D., Stanford, J., Young, C., Hicks, D., Wheeler, F., Rinehart, C., Sanchez, V., Koland, J., Muller, W., Arteaga, C. and Cook, R. (2012) HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation. Cancer Research, 72, 2672-2682.
https://doi.org/10.1158/0008-5472.CAN-11-3594
|
[3]
|
Hanna, W., Slodkowska, E., Lu, F., Nafisi, H. and Nofech-Mozes, S. (2017) Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations. Journal of Clinical Oncology, 35, 3039-3045. https://doi.org/10.1200/JCO.2016.70.5319
|
[4]
|
Slamon, D., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J. and Norton, L. (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 344, 783-792.
https://doi.org/10.1056/NEJM200103153441101
|
[5]
|
Allred, D. (2010) Issues and Updates: Evaluating Estrogen Receptor-α, Progesterone Receptor, and HER2 in Breast Cancer. Modern Pathology, 23, S52-S59.
https://doi.org/10.1038/modpathol.2010.55
|
[6]
|
Achinger-Kawecka, J., Valdes-Mora, F., Luu, P., Giles, K., Caldon, C., Qu, W., Nair, S., Soto, S., Locke, W., Yeo-Teh, N., Gould, C., Du, Q., Smith, G., Ramos, I., Fernandez, K., Hoon, D., Gee, J., Stirzaker, C. and Clark, S. (2020) Epigenetic Reprogramming at Estrogen-Receptor Binding Sites Alters 3D Chromatin Landscape in Endocrine-Resistant Breast Cancer. Nature Communications, 11, Article No. 320.
https://doi.org/10.1038/s41467-019-14098-x
|
[7]
|
Mohammed, H., Russell, I., Stark, R., Rueda, O., Hickey, T., Tarulli, G., Serandour, A., Birrell, S., Bruna, A., Saadi, A., Menon, S., Hadfield, J., Pugh, M., Raj, G., Brown, G., D’Santos, C., Robinson, J., Silva, G., Launchbury, R., Perou, C., Stingl, J., Caldas, C., Tilley, W. and Carroll, J. (2015) Progesterone Receptor Modulates ERα Action in Breast Cancer. Nature, 523, 313-317. https://doi.org/10.1038/nature14583
|
[8]
|
Campbell, E., Tesson, M., Doogan, F., Mohammed, Z., Mallon, E. and Edwards, J. (2016) The Combined Endocrine Receptor in Breast Cancer, a Novel Approach to Traditional Hormone Receptor Interpretation and a Better Discriminator of Outcome than ER and PR Alone. British Journal of Cancer, 115, 967-973.
https://doi.org/10.1038/bjc.2016.206
|
[9]
|
Yeo, B., Zabaglo, L., Hills, M., Dodson, A., Smith, I. and Dowsett, M. (2015) Clinical Utility of the IHC4 + C Score in Oestrogen Receptor-Positive Early Breast Cancer: A Prospective Decision Impact Study. British Journal of Cancer, 113, 390-395.
https://doi.org/10.1038/bjc.2015.222
|
[10]
|
Krop, I., Ismaila, N., Andre, F., Bast, R., Barlow, W., Collyar, D., Hammond, M., Kuderer, N., Liu, M., Mennel, R., Van Poznak, C., Wolff, A. and Stearns, V. (2017) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 35, 2838-2847.
https://doi.org/10.1200/JCO.2017.74.0472
|
[11]
|
Harris, L., Ismaila, N., McShane, L., Andre, F., Collyar, D., Gonzalez-Angulo, A., Hammond, E., Kuderer, N., Liu, M., Mennel, R., Van Poznak, C., Bast, R. and Hayes, D. (2016) Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 34, 1134-1150.
https://doi.org/10.1200/JCO.2015.65.2289
|
[12]
|
Martín, M., González-Rivera, M., Morales, S., de la Haba-Rodriguez, J., González-Cortijo, L., Manso, L., Albanell, J., González-Martín, A., González, S., Arcusa, A., de la Cruz-Merino, L., Rojo, F., Vidal, M., Galván, P., Aguirre, E., Morales, C., Ferree, S., Pompilio, K., Casas, M., Caballero, R., Goicoechea, U., Carrasco, E., Michalopoulos, S., Hornberger, J. and Prat, A. (2015) Prospective Study of the Impact of the Prosigna Assay on Adjuvant Clinical Decision-Making in Unselected Patients with Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor Negative, Node Negative Early-Stage Breast Cancer. Current Medical Research and Opinion, 31, 1129-1137. https://doi.org/10.1185/03007995.2015.1037730
|
[13]
|
Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M., Petry, C., Weber, K., Kronenwett, R., Brase, J. and Gnant, M. (2013) EndoPredict Improves the Prognostic Classification Derived from Common Clinical Guidelines in ER-Positive, HER2-Negative Early Breast Cancer. Annals of Oncology, 24, 640-647.
https://doi.org/10.1093/annonc/mds334
|
[14]
|
Siegel, R., Miller, K. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. https://doi.org/10.3322/caac.21442
|
[15]
|
.Pan, J., Zhou, C., Zhao, X., He, J., Tian, H., Shen, W., Han, Y., Chen, J., Fang, S., Meng, X., Jin, X. and Gong, Z. (2018) A Two-miRNA Signature (miR-33a-5p and miR-128-3p) in Whole Blood as Potential Biomarker for Early Diagnosis of Lung Cancer. Scientific Reports, 8, Article No. 16699.
https://doi.org/10.1038/s41598-018-35139-3
|
[16]
|
Yang, L., Yang, J., Li, J., Shen, X., Le, Y., Zhou, C., Wang, S., Zhang, S., Xu, D. and Gong, Z. (2015) MircoRNA-33a Inhibits Epithelial-to-Mesenchymal Transition and Metastasis and Could Be a Prognostic Marker in Non-Small Cell Lung Cancer. Scientific Reports, 5, Article No. 13677. https://doi.org/10.1038/srep13677
|
[17]
|
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., Wang, Q., Bai,H., Han, J., Tian, Y., Lu, J., Xu, T., Zhao, X., Wang, G., Cao, X., Li, F., Wang, D., Chen, Y., Bai, Y., Zhao, J., Zhao, Z., Zhang, Y., Xiong, L., He, J., Gao, S. and Wang, J. (2019) Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients with Non-Small Cell Lung Cancer with Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 5, 696. https://doi.org/10.1001/jamaoncol.2018.7098
|
[18]
|
Garon, E., Hellmann, M., Rizvi, N., Carcereny, E., Leighl, N., Ahn, M., Eder, J., Balmanoukian, A., Aggarwal, C., Horn, L., Patnaik, A., Gubens, M., Ramalingam, S., Felip, E., Goldman, J., Scalzo, C., Jensen, E., Kush, D. and Hui, R. (2019) Five-Year Overall Survival for Patients with Advanced Non-Small-Cell Lung Cancer Treated with Pembrolizumab: Results from the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 37, 2518-2527. https://doi.org/10.1200/JCO.19.00934
|
[19]
|
Inamura, K. (2018) Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers, 10, 72. https://doi.org/10.3390/cancers10030072
|
[20]
|
Solomon, B., Mok, T., Kim, D., Wu, Y., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K., Tursi, J. and Blackhall, F. (2014) First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 371, 2167-2177.
https://doi.org/10.1056/NEJMoa1408440
|
[21]
|
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A., Léna, H., Monnet, I., Rothschild, S., Cappuzzo, F., Besse, B., Thiberville, L., Rouvière, D., Dziadziuszko, R., Smit, E., Wolf, J., Spirig, C., Pecuchet, N., Leenders, F., Heuckmann, J., Diebold, J., Milia, J., Thomas, R. and Gautschi, O. (2015) Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results from the EUROS1 Cohort. Journal of Clinical Oncology, 33, 992-999. https://doi.org/10.1200/JCO.2014.58.3302
|
[22]
|
Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., Okumura, S., Nakagawa, K. and Ishikawa, Y. (2008) ATP Citrate Lyase: Activation and Therapeutic Implications in Non-Small Cell Lung Cancer. Cancer Research, 68, 8547-8554.
https://doi.org/10.1158/0008-5472.CAN-08-1235
|
[23]
|
Chen, Y., Li, K., Gong, D., Zhang, J., Li, Q., Zhao, G. and Lin, P. (2020) ACLY: A Biomarker of Recurrence in Breast Cancer. Pathology—Research and Practice, 216, Article ID: 153076. https://doi.org/10.1016/j.prp.2020.153076
|
[24]
|
Sims, A., Howell, A., Howell, S. and Clarke, R. (2007) Origins of Breast Cancer Subtypes and Therapeutic Implications. Nature Clinical Practice Oncology, 4, 516-525.
https://doi.org/10.1038/ncponc0908
|
[25]
|
Hanash, S., Ostrin, E. and Fahrmann, J. (2018) Blood Based Biomarkers beyond Genomics for Lung Cancer Screening. Translational Lung Cancer Research, 7, 327-335.
https://doi.org/10.21037/tlcr.2018.05.13
|
[26]
|
Melosky, B., Blais, N., Cheema, P., Couture, C., Juergens, R., Kamel-Reid, S., Tsao, M., Wheatley-Price, P., Xu, Z. and Ionescu, D. (2018) Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology, 25, 73.
https://doi.org/10.3747/co.25.3867
|
[27]
|
Lin, Y., Wu, J., Tseng, C., Chen, H. and Wang, L. (2018) Gjb4 Serves as a Novel Biomarker for Lung Cancer and Promotes Metastasis and Chemoresistance via Src Activation. Oncogene, 38, 822-837. https://doi.org/10.1038/s41388-018-0471-1
|